Kineta Two, LLC

Mediquest Therapeutics, Inc.

Illumigen Biosciences, Inc.

Maralee McVean

Shawn P Iadonato

Charles Lee Magness

Christina A Scherer

Mark Branum

Mark R Burns

Kevin Kennedy

Arthur Yeung

Bruce H Devens

The invention describes novel pharmaceutical compositions for the treatment of virus infections and cancer. The pharmaceutical compositions include mutant oligoadenylate synthetases (OAS) that have either enhanced cell permeability, reduced oxidative potential, improved antiviral activity, improved enzymatic activity, or absent enzymatic activity. The pharmaceutical compositions have improved drug properties and retain or have enhanced antiviral activity relative to their native forms. The pharmaceutical compositions further include chemically modified oligoadenylate synthetases, such chemical modifications being designed to increase serum stability and reduce immunogenicity in vivo. Such chemical modifications further increase drug stability and manufacturability in vitro. Compositions composed of more than ninety novel modifications are described. Also described are antibodies to polypeptides of the invention.

Oligoadenylate synthetase (OAS)

Pharmaceutical compositions for the treatment of virus infection

Oligoadenylate Synthetase (OAS)

The synthesis and use of a novel class of tumor necrosis factor (TNF&#x3b1;) inhibitors and immunomodulators are provided. Examples are those having the structures: wherein a, b and c are integers from 0 to 12, X equals NH or CHNH, Rand Reach is a hydrogen or a Cto Caliphatic; aliphatic amine; an alicyclic; aromatic; heterocycle; and halogenated forms thereof; and 

Immunomodulation with novel pharmaceutical compositions

The synthesis and use of a novel class of tumor necrosis factor (TNF&#x3b1;) inhibitors and immunomodulators are provided. These compounds have pharmacological applications as well as uses in assays relating to TNF&#x3b1; and other involved cytokines. As pharmaceuticals, these compounds are used to treat inflammatory, infectious, autoimmune or other proliferative diseases and conditions related to the unwanted presence or activity of TNF&#x3b1; and/or one or more other involved cytokines, alone or in combination with other agents. Examples of compounds of the present invention are those having the structures as shown below: wherein, a, b and c may be the same or different and are integers from 0 to 12, X equals NH or CHNH, Rand Rcan be the same or different and equal to a hydrogen or a straight or branched Cto Csaturated or unsaturated aliphatic; aliphatic amine; an alicyclic; single or multi-ring aromatic; a single or multi-ring aromatic heterocycle; a single or multi-ring saturated heterocycle and the halogenated forms thereof; and

Growing community of inventors

Seattle, WA, United States of America

Maralee McVean